ID

35868

Description

CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma; ODM derived from: https://clinicaltrials.gov/show/NCT02336386

Link

https://clinicaltrials.gov/show/NCT02336386

Keywords

Versions (1)
  1. 3/30/19 3/30/19 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

March 30, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Extramedullary Plasmacytoma NCT02336386

English

Eligibility Extramedullary Plasmacytoma NCT02336386

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
male or female patients from 18 to 80
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
biopsy-proven emp with relapsed or refractory myeloma disease. patients may be proteasome inhibitor-exposed or naive, but cannot be refractory to proteasome inhibitor therapy
Description

Extramedullary Plasmacytoma | Plasma cell myeloma recurrent | Myeloma Refractory | Exposure to Proteasome inhibitor | Proteasome inhibitor Absent | Absence Unresponsive to Treatment Proteasome inhibitor

Data type

boolean

Alias
UMLS CUI [1]
C0278619
UMLS CUI [2]
C1370446
UMLS CUI [3,1]
C0026764
UMLS CUI [3,2]
C0205269
UMLS CUI [4,1]
C0332157
UMLS CUI [4,2]
C1443643
UMLS CUI [5,1]
C1443643
UMLS CUI [5,2]
C0332197
UMLS CUI [6,1]
C0332197
UMLS CUI [6,2]
C0205269
UMLS CUI [6,3]
C1443643
disease requiring further treatment
Description

Disease Treatment required for Additional

Data type

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0332121
UMLS CUI [1,3]
C1524062
measurable disease such as m protein and objective and measurable of emp
Description

Measurable Disease | M Protein Measurable | Extramedullary Plasmacytoma Measurable

Data type

boolean

Alias
UMLS CUI [1]
C1513041
UMLS CUI [2,1]
C0700271
UMLS CUI [2,2]
C1513040
UMLS CUI [3,1]
C0278619
UMLS CUI [3,2]
C1513040
eastern cooperative oncology group (ecog) performance status of less than or equal to 2
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
meet the clinical laboratories criteria as specified in the protocol
Description

Laboratory Criteria Fulfill

Data type

boolean

Alias
UMLS CUI [1,1]
C0022877
UMLS CUI [1,2]
C0243161
UMLS CUI [1,3]
C1550543
voluntary written consent
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
female patients who are lactating, breastfeeding or pregnant
Description

Pregnancy | Breast Feeding

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
evidence of current uncontrolled cardiovascular conditions as specified in study protocol
Description

Cardiovascular Diseases Uncontrolled

Data type

boolean

Alias
UMLS CUI [1,1]
C0007222
UMLS CUI [1,2]
C0205318
requirement for other concomitant chemotherapy, immunotherapy, radiotherapy, which would be considered as a treatment of emp.
Description

Chemotherapy Other Extramedullary Plasmacytoma | Immunotherapy Other Extramedullary Plasmacytoma | Therapeutic radiology procedure Other Extramedullary Plasmacytoma

Data type

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C0205394
UMLS CUI [1,3]
C0278619
UMLS CUI [2,1]
C0021083
UMLS CUI [2,2]
C0205394
UMLS CUI [2,3]
C0278619
UMLS CUI [3,1]
C1522449
UMLS CUI [3,2]
C0205394
UMLS CUI [3,3]
C0278619
comorbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
Description

Comorbidity Systemic Study Subject Participation Status Inappropriate | Comorbidity Severe Study Subject Participation Status Inappropriate | Comorbidity Systemic Interferes with Evaluation | Comorbidity Severe Interferes with Evaluation

Data type

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0205373
UMLS CUI [1,3]
C2348568
UMLS CUI [1,4]
C1548788
UMLS CUI [2,1]
C0009488
UMLS CUI [2,2]
C0205082
UMLS CUI [2,3]
C2348568
UMLS CUI [2,4]
C1548788
UMLS CUI [3,1]
C0009488
UMLS CUI [3,2]
C0205373
UMLS CUI [3,3]
C0521102
UMLS CUI [3,4]
C1261322
UMLS CUI [4,1]
C0009488
UMLS CUI [4,2]
C0205082
UMLS CUI [4,3]
C0521102
UMLS CUI [4,4]
C1261322
ongoing or active infection, known hiv positive, active hepatitis b or c infection
Description

Communicable Disease | HIV Seropositivity | Hepatitis B | Hepatitis C

Data type

boolean

Alias
UMLS CUI [1]
C0009450
UMLS CUI [2]
C0019699
UMLS CUI [3]
C0019163
UMLS CUI [4]
C0019196
psychiatric illness/social situations that would limit compliance with study requirements
Description

Mental disorders Limiting Protocol Compliance | Social situation Limiting Protocol Compliance

Data type

boolean

Alias
UMLS CUI [1,1]
C0004936
UMLS CUI [1,2]
C0439801
UMLS CUI [1,3]
C0525058
UMLS CUI [2,1]
C0748872
UMLS CUI [2,2]
C0439801
UMLS CUI [2,3]
C0525058
known allergy to any of the study medications
Description

Hypersensitivity Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0013230
Back to the top of the page

Similar models

Eligibility Extramedullary Plasmacytoma NCT02336386

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
male or female patients from 18 to 80
boolean
C0001779 (UMLS CUI [1])
Extramedullary Plasmacytoma | Plasma cell myeloma recurrent | Myeloma Refractory | Exposure to Proteasome inhibitor | Proteasome inhibitor Absent | Absence Unresponsive to Treatment Proteasome inhibitor
Item
biopsy-proven emp with relapsed or refractory myeloma disease. patients may be proteasome inhibitor-exposed or naive, but cannot be refractory to proteasome inhibitor therapy
boolean
C0278619 (UMLS CUI [1])
C1370446 (UMLS CUI [2])
C0026764 (UMLS CUI [3,1])
C0205269 (UMLS CUI [3,2])
C0332157 (UMLS CUI [4,1])
C1443643 (UMLS CUI [4,2])
C1443643 (UMLS CUI [5,1])
C0332197 (UMLS CUI [5,2])
C0332197 (UMLS CUI [6,1])
C0205269 (UMLS CUI [6,2])
C1443643 (UMLS CUI [6,3])
Disease Treatment required for Additional
Item
disease requiring further treatment
boolean
C0012634 (UMLS CUI [1,1])
C0332121 (UMLS CUI [1,2])
C1524062 (UMLS CUI [1,3])
Measurable Disease | M Protein Measurable | Extramedullary Plasmacytoma Measurable
Item
measurable disease such as m protein and objective and measurable of emp
boolean
C1513041 (UMLS CUI [1])
C0700271 (UMLS CUI [2,1])
C1513040 (UMLS CUI [2,2])
C0278619 (UMLS CUI [3,1])
C1513040 (UMLS CUI [3,2])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status of less than or equal to 2
boolean
C1520224 (UMLS CUI [1])
Laboratory Criteria Fulfill
Item
meet the clinical laboratories criteria as specified in the protocol
boolean
C0022877 (UMLS CUI [1,1])
C0243161 (UMLS CUI [1,2])
C1550543 (UMLS CUI [1,3])
Informed Consent
Item
voluntary written consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Pregnancy | Breast Feeding
Item
female patients who are lactating, breastfeeding or pregnant
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Cardiovascular Diseases Uncontrolled
Item
evidence of current uncontrolled cardiovascular conditions as specified in study protocol
boolean
C0007222 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
Chemotherapy Other Extramedullary Plasmacytoma | Immunotherapy Other Extramedullary Plasmacytoma | Therapeutic radiology procedure Other Extramedullary Plasmacytoma
Item
requirement for other concomitant chemotherapy, immunotherapy, radiotherapy, which would be considered as a treatment of emp.
boolean
C0392920 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
C0278619 (UMLS CUI [1,3])
C0021083 (UMLS CUI [2,1])
C0205394 (UMLS CUI [2,2])
C0278619 (UMLS CUI [2,3])
C1522449 (UMLS CUI [3,1])
C0205394 (UMLS CUI [3,2])
C0278619 (UMLS CUI [3,3])
Comorbidity Systemic Study Subject Participation Status Inappropriate | Comorbidity Severe Study Subject Participation Status Inappropriate | Comorbidity Systemic Interferes with Evaluation | Comorbidity Severe Interferes with Evaluation
Item
comorbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
boolean
C0009488 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C2348568 (UMLS CUI [1,3])
C1548788 (UMLS CUI [1,4])
C0009488 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C2348568 (UMLS CUI [2,3])
C1548788 (UMLS CUI [2,4])
C0009488 (UMLS CUI [3,1])
C0205373 (UMLS CUI [3,2])
C0521102 (UMLS CUI [3,3])
C1261322 (UMLS CUI [3,4])
C0009488 (UMLS CUI [4,1])
C0205082 (UMLS CUI [4,2])
C0521102 (UMLS CUI [4,3])
C1261322 (UMLS CUI [4,4])
Communicable Disease | HIV Seropositivity | Hepatitis B | Hepatitis C
Item
ongoing or active infection, known hiv positive, active hepatitis b or c infection
boolean
C0009450 (UMLS CUI [1])
C0019699 (UMLS CUI [2])
C0019163 (UMLS CUI [3])
C0019196 (UMLS CUI [4])
Mental disorders Limiting Protocol Compliance | Social situation Limiting Protocol Compliance
Item
psychiatric illness/social situations that would limit compliance with study requirements
boolean
C0004936 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0525058 (UMLS CUI [1,3])
C0748872 (UMLS CUI [2,1])
C0439801 (UMLS CUI [2,2])
C0525058 (UMLS CUI [2,3])
Hypersensitivity Investigational New Drugs
Item
known allergy to any of the study medications
boolean
C0020517 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial